European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories

European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories

16/02/2012

Final recommendations confirm interim advice given; medicines can continue to be prescribed as previously

Continuing its review on the shortcomings in quality assurance identified at Ben Venue Laboratories, Ohio, United States, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial advice and given final recommendations for 12 out of 14 centrally authorised medicines manufactured at this site (Angiox, Busilvex, Vidaza, Vistide, Velcade, Ecalta diluent, Soliris, Cayston, Luminity, Mepact, Torisel and Vibativ). These medicines can continue to be prescribed as previously.

On 13 January 2012, the United Kingdom’s medicines regulatory agency (MHRA) on behalf of the European regulatory network issued a restricted Good Manufacturing Practice Certificate to Ben Venue in order to stop the European Union (EU) supply of non-essential medicines from Ben Venue, while allowing the continued supply of essential medicines.

For Vistide and Cayston, Ben Venue Laboratories, Ohio has already been removed as manufacturing site from the marketing authorisation. For all other medicines the CHMP has now asked the marketing authorisation holders to remove this manufacturing site.

For Vibativ and Luminity, which are currently not marketed in the EU and for which no alternative manufacturer or formulation is available, the Committee recommends the suspension of the marketing authorisations until a suitable alternative manufacturing site is approved. For the remaining 10 medicines, the CHMP recommends maintaining the marketing authorisations as alternative suppliers or formulations are available.

The review of the two other centrally authorised medicines manufactured at this site, Caelyx and Ceplene, is still ongoing and is expected to be concluded in March 2012.

Notes

    The European review of the centrally authorised medicines Angiox, Busilvex, Cayston, Ecalta, Luminity, Mepact, Soliris, Torisel, Velcade, Vibativ, Vidaza and Vistide, manufactured at the Ben Venue site in Ohio, was conducted in the context of a formal review, initiated at the request of the European Commission under Article 20 of Regulation (EC) No 726/2004, on 17 November 2011. More information on these medicines can be found in the relevant European public assessment reports (EPARs).
    The press releases on the interim recommendations for medicines manufactured at Ben Venue dated 22 November 2011, 9 and 13 December 2011 are available on the Agency's website.

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.